Literature DB >> 10025886

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients.

C Besses1, F Cervantes, A Pereira, L Florensa, F Solé, J C Hernández-Boluda, S Woessner, J Sans-Sabrafen, C Rozman, E Montserrat.   

Abstract

To determine the clinicohematological factors predictive for the appearance of major vascular complications (MVC) in patients with essential thrombocythemia (ET), 148 consecutive such patients were retrospectively assessed for the development of MVC during a median follow-up of 58.5 months. Seventy-seven patients had vascular risk factors, and 37 a history of MVC at ET diagnosis. Forty-nine MVC were registered in 33 patients during the follow-up period. The actuarial probability of MVC was 27% at 6 years in the whole series, 35.6% for patients above 60 years, and 21.4% for patients younger than 60 years, whereas only one of the 36 patients younger than 45 years had MVC. At multivariate analysis, age >60 years, history of major ischemia and hypercholesterolemia were the variables associated with an increased MVC risk. These results suggest that all ET patients above 60 years should be treated, whereas in younger patients treatment decisions should be primarily based on the existence of risk factors for MVC.

Entities:  

Mesh:

Year:  1999        PMID: 10025886     DOI: 10.1038/sj.leu.2401270

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  31 in total

1.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

2.  Off-pump coronary artery surgery in a patient with essential thrombocythaemia: two life-threatening complications in the same patient.

Authors:  Kaan Kaya; Raif Cavolli; Alpaslan Telli; Refik Tasoz
Journal:  BMJ Case Rep       Date:  2009-08-25

Review 3.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

Review 4.  Polycythaemia vera and essential thrombocythaemia in the elderly.

Authors:  P J van Genderen; M M Troost
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

5.  How I treat essential thrombocythemia.

Authors:  Philip A Beer; Wendy N Erber; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

6.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

7.  Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.

Authors:  Roberto Latagliata; Angela Rago; Antonio Spadea; Cristina Santoro; Ida Carmosino; Massimo Breccia; Laura Napoleone; Angelo Fama; Francesca Biondo; Paola Volpicelli; Federico Vozella; Caterina Stefanizzi; Maria Concetta Petti; Giuliana Alimena; Maria Gabriella Mazzucconi
Journal:  Int J Hematol       Date:  2009-08-22       Impact factor: 2.490

8.  JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?

Authors:  Nicole Kucine; Ross L Levine
Journal:  Ther Adv Hematol       Date:  2011-08

9.  Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.

Authors:  Ayako Kamiunten; Kotaro Shide; Takuro Kameda; Masaaki Sekine; Yoko Kubuki; Masafumi Ito; Takanori Toyama; Noriaki Kawano; Kousuke Marutsuka; Kouichi Maeda; Masanori Takeuchi; Hiroshi Kawano; Seiichi Sato; Junzo Ishizaki; Keiichi Akizuki; Yuki Tahira; Haruko Shimoda; Tomonori Hidaka; Kiyoshi Yamashita; Hitoshi Matsuoka; Kazuya Shimoda
Journal:  Int J Hematol       Date:  2018-02-27       Impact factor: 2.490

10.  The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia.

Authors:  Danijela Lekovic; Mirjana Gotic; Natasa Milic; Predrag Miljic; Mirjana Mitrovic; Vladan Cokic; Ivo Elezovic
Journal:  Med Oncol       Date:  2014-09-16       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.